Review
NN-2211 Novo Nordisk
Affiliations
- PMID: 12789615
Item in Clipboard
Review
NN-2211 Novo Nordisk
IDrugs.
2003 Mar.
Abstract
Novo Nordisk A/S, under license from Scios Inc, is developing NN-2211, a stable analog of the naturally occurring peptide hormone glucagon-like peptide 1 (GLP-1), which stimulates insulin release in response to increases in blood sugar levels, for the potential treatment of type 2 diabetes.
Similar articles
-
Therapies for the treatment of type 2 diabetes mellitus based on incretin action.Minerva Endocrinol. 2006 Jun;31(2):133-47. Minerva Endocrinol. 2006. PMID: 16682937 Review.
-
Liraglutide (Victoza) for type 2 diabetes.Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7. Med Lett Drugs Ther. 2010. PMID: 20360660
-
[Glucagon-like peptide-1(GLP-1)].Nihon Rinsho. 2004 Jun;62(6):1175-80. Nihon Rinsho. 2004. PMID: 15206160 Review. Japanese.
-
BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.Curr Opin Investig Drugs. 2007 Oct;8(10):842-8. Curr Opin Investig Drugs. 2007. PMID: 17907061 Review.
-
Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.Clin Sci (Lond). 1998 Sep;95(3):325-9. Clin Sci (Lond). 1998. PMID: 9730852 Clinical Trial.
Cited by
-
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.Rev Diabet Stud. 2005 Summer;2(2):61-9. doi: 10.1900/RDS.2005.2.61. Epub 2005 Aug 10. Rev Diabet Stud. 2005. PMID: 17491680 Free PMC article.